Abstract
Background The adverse effects of COVID-19 pandemic on the mental health of high-risk group patients for morbidity and mortality and its impact on public health in the long term have not been clearly determined.
Objective To determine the level of COVID-19 related transmission fear and anxiety in healthcare workers and patients with primary immunodeficiency disorder (PID), severe asthma, and the ones with other comorbidities.
Methods The healthcare workers and patients with PID, severe asthma (all patients receiving biological agent treatment), malignancy, cardiovascular disease, hypertension (90% of patients receiving ACEI or ARB therapy), diabetes mellitus (42 % of patients receiving DPP-4 inhibitor therapy) were included in the study. A total of 560 participants, 80 individuals in each group, were provided. The hospital anxiety and depression scale (HADS) and Fear of illness and virus evaluation (FIVE) scales were applied to the groups with face to face interview methods.
Results The mean age was 49.30 ± 13.74 years and 306 (55 %) were female. The FIVE Scale and HADS-A scale scores of health care workers were significantly higher than other groups scores (p = 0.001 and 0.006). The second-highest scores belonged to patients with PID. There was no significant difference between the groups for the HADS-D score (p=0.07). The lowest score in all scales was observed in patients with hypertension.
Conclusions This study demonstrated that in the pandemic process, patients with primary immunodeficiency, asthma patients, and other comorbid patients, especially healthcare workers, should be referred to the centers for the detection and treatment of mental health conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local ethics committee of Necmettin Erbakan University, Meram Faculty of Medicine with the 2020/2448 ID number, and the study was conducted according to the 1975 Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript is available.
List of abbreviations
- ACEI
- Angiotensin converting enzyme inhibitors
- ARB
- Angiotensin II receptor blocker
- ARDS
- Acute respiratory distress syndrome
- AUC
- Area under the curve
- CI
- Confidence interval
- COVID-19
- Coronavirus disease 2019
- CID
- Combined immunodeficiency
- CVID
- Common variable immune deficiency
- CVS
- Cardiovascular system
- DM
- Diabetes mellitus
- DPP-4
- Dipeptidyl peptidase-4
- FIVE
- Fear of illness and virus evaluation
- HADS
- Hospital anxiety and depression scale
- HADS-A
- Hospital anxiety and depression scale, anxiety subscale
- HADS-D
- Hospital anxiety and depression scale, depression subscale
- HCC
- Hepatocellular carcinoma
- HT
- Hypertension
- NK
- Natural killer
- PID
- Primary immunodeficiency disorder
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus-2
- SCIG
- Subcutaneous immunoglobulin
